Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Exclusion Criteria

• •Tumors of mucinous, low-grade serous, squamous cell, small cell neuroendocrine subtypes, MMMT tumors absent an epithelial component on recent biopsy, or non-epithelial ovarian cancers (e.g., germ cell tumors, Sex-cord tumors).
• •Bowel obstruction within last 3 months prior to screening.
• •Active urinary tract infection, pneumonia, other systemic infections.
• •Active gastrointestinal bleeding.
• •Known current central nervous system (CNS) metastasis.
• •Inflammatory diseases of the bowel.
• •History of HIV infection.
• •Active hepatitis B virus or hepatitis C virus within 4 weeks prior to study.
• •History of thromboembolic event within the prior 3 months.
• •Contraindications for intraperitoneal (IP) catheter placement: Bowel obstruction with distended abdomen, rigid abdomen with bulky anterior wall carcinomatosis, abdominal wall hernia mesh that precludes laparoscopic entry to abdomen.
• •Clinically significant cardiac disease at screening (New York Heart Association Class III/IV).
• •Acute cerebrovascular event(s) such as cerebrovascular accident (CVA) or transient ischemic attack (TIA) in previous 6 months.
• •Oxygen saturation \<90%.
• •Received prior virus-based gene therapy or therapy with cytolytic virus of any type.
• •Receiving concurrent antiviral agent.
• •Prior malignancy of other histology active within previous 3 years except for locally curable cancers apparently cured such as basal/squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of cervix or breast, any other stage I/II local malignancies.
• •Received chemotherapy, radiotherapy, other anti-cancer biologic therapies within 4 weeks prior to planned treatment.
• •Underwent surgery within 4 weeks, or have insufficient recovery from surgical-related trauma or wound healing, prior to first study treatment in either Arm.
• •Receiving immunosuppressive therapy or steroids (except acute concurrent corticosteroid of no more than 20 mg per day for medical management with prednisolone equivalent.
• •Symptomatic malignant ascites or pleural effusions defined as rapidly progressive ascites with abdominal distension and gastrointestinal dysfunction, pleural effusions with respiratory difficulties requiring frequent paracentesis \> once every 14 days.
• •Known hypersensitivity to gentamicin.